Investor Presentaiton

. . . • New drug reporting: Data elements Whether there was a breakthrough designation or priority review granted and any support documentation Date and price paid for acquisition of the new prescription drug Estimate of the average number of patients who will be prescribed the new prescription drug each month Research and development costs associated with the new prescription drug that were paid using public funds 11

View entire presentation